OLIG2 and cancer: In collaboration with Curtana Pharmaceuticals (San Diego, CA), we generated an orally bioavailable small molecule (397 kD) Olig2 inhibitor, CT-179, the first drug targeting bHLH transcription factors for cancer treatment.